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Abstract: The present work described the development of two simple, accurate, 
rapid, cost effective and reproducible UV-Spectrophotometric methods for 
the simultaneous estimation of Quinfamide and Mebendazole in bulk and in 
laboratory mixture using 0.01M methanolic HCl as a solvent. The absorption 
maximum for Quinfamide and Mebendazole were found to be at 260.00 nm 
and 232.40 nm respectively. Beer’s - lamberts was followed in concentration 
ranges of 1 - 6 μg/mL for Quinfamide and 2- 12 μg/mL for Mebendazole. 
The percentage recovery of Quinfamide and mebendazole ranged from 98.48 
to 99.08 and 98.83 to 99.62 (Method I); from 98.14 to 98.93 and 99.16 to 
99.35 (Method II) for Quinfamide and Mebendazole. The established methods 
were sensible for simultaneous quantitative determination of both these drugs 
in fixed dose combinations. Validation of both these methods was performed 
as per ICH guidelines.  The developed methods can routinely be used for 
estimation of both these drugs in their combined dosage form.
Keyword: Quinfamide; Mebendazole, Vierodt’s Method and Multi-component 
Mode, UV-Spectrophotometer, Validation.
1. INTRODUCTION
The substantial increase in the demand of combined dosage form for advanced 
therapeutic achievement has created avenues for enhanced pharmaceutical 






acceptability [1]. Simultaneous equation (Vierodt’s Method) is relevant for 
the estimation of those drugs where the spectra of the drugs overlay accurately 
and multicomponent analysis can be useful  to any extent of spectral overlap 
provided that two or more spectra are not similar exactly [2]. The fundamental 
development behind these methods is the measurement of some property which 
is proportional to amount of analyte in sample. Intestinal parasitic diseases are 
distributed nearly throughout the world, with huge rates in many regions [3]. 
Invasive amoebiasis and helminthiasis is a chief health and social difficulty 
in western and South-eastern Africa, South-east Asia, China, and Latin 
America, specially in Mexico [4]. The combination of Quinfamide (QFN) and 
Mebendazole (MEB) is used in the treatment of amebiasis and helminthiasis 
and both drugs give effective and safe results. QFN is chemically [1-(2, 
2-dichloroacetyl)-3, 4-dihydro-2H-quinolin-6-yl] furan-2-carboxylate [5] 
(Fig. 1) having antiparasitic properties consist of dichloroacetamide function 
[6, 7].QFN is an antiamoebic agent used in the intestinal lumen, is absorbed 
at least possible levels, and is discard within 48 h, has been recognized to 
be an efficient clinical antiamoebic in 80 to 90% of cases linking a single 
day of treatment [8, 9]. MEB chemically, Methyl-5-benzoyl-2-benzimidazole 
carbamate (Fig. 2) is broad spectrum antihelmintic agent [10]. It is BCS class 
II drug showing low solubility and high permeability [11, 12]. 
Figure 1: Molecular Structure of Quinfamide.
Literature survey revealed no single established analytical method for the 
simultaneous determination of Quinfamide and Mebendazole in pharmaceutical 
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formulation.  Hence, present research work was undertaken with the objective 
of developing a newer, simple, rapid and cheap simultaneous equation method 
and multi-component method for the analysis of Quinfamide and Mebendazole 
in bulk form and laboratory mixture. 
2. MATERIALS AND METHODS
2.1 Chemicals 
Quinfamide bulk drug was supplied as a gift sample by RPG Life Science Pvt. 
Ltd., Mumbai, (MS.) India. Mebendazole bulk drug was supplied as a gift 
sample by Watson Pharmaceuticals Pvt. Ltd., Mumbai, (MS) India. 0.01 M 
methanolic HCl was used throughout the experimental Work.
2.2 Instrumentation
A UV-Visible spectrophotometer (2450 Shimadzu and UV-1601, software 
UV Probe 2.21). The spectral bandwidth 1 nm was implemented for all 
spectroscopic measurements, using a pair of 10 mm matched quartz cells. 
2.3 Preparation of Standard Stock Solution 
Standard Stock solution of QFN and MEB was prepared by dissolving 10 mg in 
100 mL of 0.01M methanolic HCl in different flask to obtain the concentration 
of 100 μg/mL of each drug. 
2.4 Selection of Wavelengths  
From these prepared solution, 1mL  of QFN and  MEB were  transferred into 
two separate 10 mL volumetric flask and volume was made up to the mark 
using 0.01M methanolic HCl  to obtain concentration each of 10 μg/mL; the 
resultant solution was checked in UV-range (400 - 200 nm) in 1.0 cm cell 
beside solvent blank. The overlain spectrum was determined absorbance of 
mixture of two drugs (Fig. 3).






2.5 Preparation of Calibration Curve
Calibration curve of QFN was prepared using standard stock solution by taking 
appropriate volumes in the range of (0.1 to 0.6 mL) were transferred into series 
of 10 mL volumetric flask to obtain concentration of 1, 2, 3, 4, 5, and 6 μg/mL. 
The absorbance of these solutions was recorded initially at 260 nm.
Calibration curve of MEB was prepared using standard stock solution by 
taking appropriate volumes in the range of (0.2 to 1.2 mL) were transferred to 
series of  10 mL volumetric and volume were prepared up to the mark using 
0.01M  methanolic HCl to get concentrations in range of 2, 4, 6, 8, 10 and 
12 μg/mL. The absorbance of this solution was measured at 232.40 nm. The 
overlain spectrum for mixture (10 μg/ ml each) is shown in (Fig. 4).
2.6 Method – I (Vierodt’s Method)
Absorbance was measure at the maximum absorption wavelength of two 
drugs in quantitative determination of two drugs by simultaneous equation. 
Two wavelengths 260 nm and 232.40 nm for QFN and MEB were selected 
Figure 3: Overlain spectra of Quinfamide and Mebendazole.
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and sixed mixed standards solutions QFN and MEB were prepared in 0.01M 
methanolic HCl. All prepared standard solution were scanned over the range 
of 400 – 200 nm in simultaneous mode using two sampling wavelength 260 
nm (λmax of QFN) and 232.40 nm (λmax of MEB). The absorbance and the E 
(1%1, 1cm) at the particular wavelength were calculated and substituted in the 
following Vierodt’s equation. Demographic parameters like slope, intercept, 
correlation coefficient, standard deviation, relative standard deviation was 
calculated.
 Cx = A2 ay1−A1 ay2/ ax2 ay1−ax1ay2 (1)
 Cy = A1 ax2−A2 ax2/ ax2 ay1−ax1ay2 (2)
Where,
Cx and Cy are the concentrations of x (QFN) and y (MEB)






A1 is the absorbance of mixture at λ1
A2 is the absorbance of mixture at λ2
ax1 is the E(1%, 1cm) value of QFN at λ1
ax2 is the E(1 %, 1cm) value of QFN at λ2
ay1 is the E(1%, 1cm) value of MEB at λ1
ay2 is the E(1%, 1cm) value of MEB at λ2
A1 is the absorbance of mixture at 260nm, A2 is the absorbance of mixture at 
232.40nm and ax1= (864), ax2= (340), ay1= (530), ay2= (1104) are E (1%, 1 
cm) of QFN and MEB at 260 nm and 232.40 nm.
2.7 Method- II (Multi-component mode of analysis)
Mixed standard solutions of QFN and MEB were prepared six times in 0.01M 
methanolic HCl. In the multicomponent mode, all the standards were scanned 
over the range of 400 - 200 nm, using two sampling wavelength 260 nm (λ 
max of QFN) and 232.40 nm (λmax of MEB). The scanning data were used 
to resolve the concentrations of two drugs in solution of laboratory mixture 
(Fig. 5).
Figure 5: Overlain spectra of Quinfamide (QFN) and Mebendazole 
(MEB).
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2.8 Analysis of Laboratory Formulation
The laboratory formulation was prepared containing 150 mg of QFN and 
300 mg of MEB along with commonly used excipient,   a quantity of 
powder drug equivalent 10 mg of QFN and 20 mg of MEB was transferred 
into 100 mL volumetric flask containing 60 mL 0.01M methanolic HCl, 
sonicated for 20 min and the aggregate was load up to marking and filtered 
through Whatmann filter paper (no.41).  Further, the solution was diluted 
with 0.01M methanolic HCl to obtain the final concentration 4 μg/mL for 
QFN and 8 μg/mL for MEB. Absorbance of this solution was measured at 
260 nm and 232.40 nm. The quantitative estimation of both these drugs 
were performed solving simultaneous equation (1)  & equation (2) (Method 
I). The equivalent quantities of solutions were regulated to investigate in the 
multicomponent mode present in the instrument (UV-Spectrophotometer 
1601). The solution was studied over the wavelength the range of 400 - 
200 nm; the concentration of drugs were stored by analysis of spectral 
information of the sample solution with reference to the mixed standards 
(Method II). The analysis procedure was repeated six times with laboratory 
formulations (Table 1).

















N = Number of determinations (N = 6)
2.9 Method Validation Parameters
The method was developed and validated according as per ICH guideline [13].
All parameter such as accuracy, precision, linearity, DL and QL and for the 
analytes were found to be within the limit and satisfactory.
2.10 Accuracy
The accuracy of the suggested method was confirmed by recovery investigation 






levels (80%, 100%, and 120%) in a period of the area of linearity for both the 
drugs (Table 2 and 3).

















1.6 3.6 3.52 98.77 0.80
2 4 3.96 99.08 0.31
2.4 4.4 4.33 98.48 1.08
MEB
4
3.2 7.2 7.17 99.62 0.17
4 8 7.97 99.62 0.30
4.8 8.8 8.43 98.83 1.47
N = Number of determinations (N = 3)
2.11 Precision
Assay method precision (intra-day precision) was established by carrying 
out four assay of test samples by the same analyst with the same equipment; 
whereas inter-day precision effect evaluation of modification in analysis when 
the method is used on different days. The % RSD values of the response was 
found to be less than 2 % (Table 4 and 5) for intra-day and inter-day precision, 
respectively.
Repeatability of the scanning device and injection was studied by applying 
and analyzing samples six times. The % RSD values were less than 2.0 (Table 
6 and 7), representing that the method is repeatable and irreducible.


















1.6 3.6 3.53 98.14 0.96
2 4 3.92 98.16 0.66
2.4 4.4 4.35 98.93 0.47
MEB
4
3.2 7.2 7.15 99.35 0.34
4 8 7.94 99.33 0.42
4.8 8.8 8.72 99.16 0.37
N = Number of determinations (N = 3)
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Mean ± SD % 
RSD
Mean ± SD % 
RSD
QFN
2 1.94 ± 0.013 0.34 1.94 ±0.024 1.03
3 2.98 ±0.005 0.17 2.98 ±0.007 0.81
4 3.91 ±0.030 0.38 3.91 ±0.024 0.40
MEB
4 3.95 ±0.018 0.21 3.95±0.018 0.56
6 5.96±0.007 0.11 5.95±0.012 0.75
8 7.91±0.299 0.25 7.90±0.076 1.47
N = Number of determinations (N = 3)
















2 1.93 ± 0.011 0.59 1.94 ±0.020 1.06
3 2.98 ±0.020 0.70 2.95 ±0.049 1.66
4 3.90 ±0.049 1.26 3.92 ±0.037 0.96
MEB
4 3.95 ±0.017 0.438 3.95±0.032 0.81
6 5.91 ±0.020 0.35 5.94 ±0.020 0.35
8 7.93 ±0.060 0.767 7.89 ±0.105 1.33
N = Number of determinations (N = 3)
Table 6: Results of repeatability study.










QFN 98.08  ± 1.10 1.12 97.79 ± 1.17 1.20
MEB 99.08  ± 0.52 0.52 99.10 ± 0.49 0.50







Sensitivity of the method was predicted as Detection Limit (DL) and 
Quantification Limit (QL). The DL and QL were estimated by the use of the 
comparison DL = 3.3 Х ASD/S and QL = 10 Х ASD/S; where, ‘ASD’ is Average 
standard deviation of the peak height and areas of the drug (n = 3), taken as 
a measure of noise, and ‘S’ is the slope of the corresponding calibration plot. 
The procedure was repeated in triplicate. In method I LOD and LOQ for QFN 
was 0.26 and 0.80 μg as well as for MEB 0.26 and 0.79 μg and in method II for 
QFN was 0.30 and 0.91 μg as well as for MEB 0.25 and 0.77 μg, respectively.
3. RESULTS AND DISCUSSION
Quinfamide and Mebendazole depicted good linearity over the concentration 
range of 1 - 6 μg/ml and 2 - 12 μg/ml using 0.01M methanolic HCl for these 
Table 7: Validation Parameters for Quinfamide and Mebendazole.
Parameters QFN MEB
Method I Method II Method I Method II
Working 
Wavelengths(nm)
260 260 232.40 232.40
Linearity Range 
(μg/mL)
1 – 6 1− 6 2 − 12 2−12
Precision(%RSD)
Inter−day (n = 3) 0.40 −1.03 0.96 − 1.66 0.56 − 1.47 0.35 − 1.33
Intra−day (n = 3) 0.17−0.38 0.59 − 1.26 0.11 − 0.25 0.35 − 0.76
Repeatability
(n = 6)
1.12 1.20 0.52 0.50
Ruggedness
[%RSD]
Analyst I (n = 6) 0.89 0.88 1.36 0.23
Analyst II ( n= 6) 0.85 0.55 0.53 0.91
% Recovery
(n = 3)




















two methods at their particular λ max with coefficient correlation. Laboratory 
formulations were analyzed. The amounts of QFN and MEB determined by 
‘Method I’ was found to be 98.29 and 98.93, respectively; while, by ‘Method 
II’, it was found to be 98.95 and 99.29, respectively. The proposed method 
was validated as per ICH guideline. The percentage recovery was decisive by 
designing by mean percentage recovery. It was studied at 80, 100 and 120 %. 
Precision was determined as repeatability (% RSD is less than 2.0) and inter-
day- intra-day deviation (% RSD is less than 2.0) for both drugs. The ruggedness 
of the process was examined by two particular analysts keeping same operative 
and environmental conditions.  Sensitivity of the method was examined as limit 
of detection and limit of quantification. The analyzed data like, % recovery, 
repeatability data, ruggedness data are presented in details (Table 7).
CONCLUSION
The developed methods were found to be simple, rapid, reproducible and precise 
and can be used for quality control analysis of Quinfamide and Mebendazole 
in bulk and may be conveniently extended towards determination of drug in 
pharmaceutical formulations.
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• UV- Ultra Violet
• VIS- Visible
• Μg/mL- Micro Gram/ Milliliter
• mL-Milliliter
• DL-Detection of Limit
• QL-Quantification of Limit
• ASD-Average Standard Deviation
• % RSD-Percentage Relative Standard Deviation 
• SD-Standard Deviation
• ICH-International Council on Harmonization 
